The downgrade from Buy to Hold by a Stifel analyst suggests a bearish outlook on Aclaris Therapeutics, which is likely to negatively impact investor sentiment in the short term. The substantial reduction in the price target from $20 to $2 indicates a significant revision of the company's valuation, which could lead to a decrease in stock price as the market adjusts to the new analyst expectations.